Discussion
Karyopharm Therapeutics is seeking accelerated approval for its investigational therapy selinexor in the United States as a treatment for heavily treated multiple myeloma…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
Discussion
Discussion
Older multiple myeloma patients who are unable to receive a stem cell transplant could receive Ninlaro (ixazomib) as part of their first line-therapy instead…
Discussion
A triple combination treatment — dendritic cell vaccination plus Revlimid (lenalidomide) and an anti-PD-1 checkpoint inhibitor — led to stronger anti-tumor immune responses against myeloma…
Discussion
Takeda‘s proteasome inhibitor Ninlaro (ixazomib) prevents multiple myeloma from progressing or returning when given as a maintenance therapy to patients who responded to first-line therapy…
Discussion
Multiple myeloma patients whose cancer progresses early after first-line therapy have a greater economic burden compared to those whose disease progresses later, a recent study…
Discussion
Twice‐weekly Ninlaro (ixazomib) plus Revlimid (lenalidomide) and dexamethasone can improve long-term outcomes in patients with newly diagnosed multiple…
